Regeneron Pharmaceuticals Inc (REGN) Price Target Raised to $400.00

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) had its target price lifted by investment analysts at Barclays PLC from $375.00 to $400.00 in a research note issued on Monday, May 8th. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Barclays PLC’s target price suggests a potential downside of 12.54% from the stock’s current price.

REGN has been the topic of several other reports. Oppenheimer Holdings Inc. assumed coverage on Regeneron Pharmaceuticals in a research report on Thursday, March 16th. They set a “hold” rating on the stock. JPMorgan Chase & Co. set a $440.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research note on Sunday, January 22nd. Leerink Swann set a $448.00 price target on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, March 28th. Canaccord Genuity set a $450.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research note on Friday, February 3rd. Finally, BTIG Research reissued a “buy” rating and issued a $460.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, March 29th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $432.21.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 1.60% on Monday, hitting $450.01. The stock had a trading volume of 996,846 shares. Regeneron Pharmaceuticals has a 12 month low of $325.35 and a 12 month high of $462.96. The stock has a 50 day moving average of $397.84 and a 200-day moving average of $380.88. The stock has a market cap of $47.51 billion, a PE ratio of 54.47 and a beta of 1.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.42. Regeneron Pharmaceuticals had a return on equity of 22.51% and a net margin of 18.10%. The firm had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.30 billion. During the same period in the prior year, the firm earned $2.57 EPS. The firm’s revenue was up 9.8% on a year-over-year basis. Equities research analysts anticipate that Regeneron Pharmaceuticals will post $12.67 EPS for the current year.

WARNING: This report was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.chaffeybreeze.com/2017/05/19/regeneron-pharmaceuticals-inc-regn-price-target-raised-to-400-00-at-barclays-plc-updated.html.

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,000 shares of the stock in a transaction on Wednesday, March 29th. The shares were sold at an average price of $400.00, for a total transaction of $400,000.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $400,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael S. Brown sold 3,000 shares of the stock in a transaction on Friday, May 12th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the transaction, the director now owns 3,000 shares in the company, valued at $1,350,000. The disclosure for this sale can be found here. 10.40% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of REGN. Ngam Advisors L.P. acquired a new position in Regeneron Pharmaceuticals during the third quarter worth about $28,309,000. Boston Common Asset Management LLC increased its position in Regeneron Pharmaceuticals by 26.5% in the third quarter. Boston Common Asset Management LLC now owns 11,592 shares of the biopharmaceutical company’s stock worth $4,660,000 after buying an additional 2,431 shares during the last quarter. Sei Investments Co. increased its position in Regeneron Pharmaceuticals by 3.6% in the third quarter. Sei Investments Co. now owns 197,217 shares of the biopharmaceutical company’s stock worth $79,285,000 after buying an additional 6,801 shares during the last quarter. Biondo Investment Advisors LLC increased its position in Regeneron Pharmaceuticals by 402.0% in the third quarter. Biondo Investment Advisors LLC now owns 11,470 shares of the biopharmaceutical company’s stock worth $4,611,000 after buying an additional 9,185 shares during the last quarter. Finally, Princeton Capital Management Inc. increased its position in Regeneron Pharmaceuticals by 14.6% in the third quarter. Princeton Capital Management Inc. now owns 2,235 shares of the biopharmaceutical company’s stock worth $899,000 after buying an additional 284 shares during the last quarter. Institutional investors own 68.83% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

5 Day Chart for NASDAQ:REGN

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply